Corcept Therapeutics Inc CORT
9 trading plans running, 32 Form 144 notices for $103.7M
10-Q, 10-K and Form 144What CORT's directors and officers said they would sell, before they sold: trading plans the company reports each quarter, and the Form 144 notices sellers file on the day of a planned sale. Most of these sales are routine, such as selling shares from vesting stock awards.
Plans adopted or ended
Trading plans · XBRL, 10-Q and 10-K
From Nov 27, 2024 to May 31, 2028. The thin line is today; a filled bar is a plan still running, a paler one has ended or expired. The ten newest plans are drawn; all are in the table.
| Insider | What | Date | Reported in |
|---|---|---|---|
| William Guyer Chief Development Officer |
Adopted 10b5-1 plan | Aug 20, 2026 | 10-Q Nov 3, 2026 |
| Atabak Mokari Chief Financial Officer |
Adopted 10b5-1 plan | Aug 13, 2026 | 10-Q Nov 3, 2026 |
| Daniel N. Swisher, Jr. Director |
Adopted 10b5-1 plan | Aug 3, 2026 | 10-Q Nov 3, 2026 |
| Joseph K. Belanoff, M.D. Chief Executive Officer and Director |
Adopted 10b5-1 plan | Jun 11, 2026 | 10-Q Jul 29, 2026 |
| Joseph D. Lyon Chief Accounting & Technology Officer |
Adopted 10b5-1 plan | Jun 10, 2026 | 10-Q Jul 29, 2026 |
| David L. Mahoney Director |
Adopted 10b5-1 plan | May 19, 2026 | 10-Q Jul 29, 2026 |
| James N. Wilson Director |
Adopted 10b5-1 plan | Mar 12, 2026 | 10-Q Apr 30, 2026 |
| Atabak Mokari Chief Financial Officer |
Adopted 10b5-1 plan | Dec 12, 2025 | 10-K Feb 24, 2026 |
| Sean Maduck President, Corcept Endocrinology |
Adopted 10b5-1 plan | Dec 8, 2025 | 10-K Feb 24, 2026 |
| William Guyer Chief Development Officer |
Adopted 10b5-1 plan | Nov 27, 2024 | 10-K Feb 26, 2025 |
| Joseph K. Belanoff, M.D. Chief Executive Officer |
Adopted 10b5-1 plan | Nov 26, 2024 | 10-K Feb 26, 2025 |
| Sean Maduck President, Endocrinology |
Adopted 10b5-1 plan | Sep 5, 2024 | 10-Q Oct 30, 2024 |
| Joseph D. Lyon Chief Accounting and Technology Officer |
Adopted 10b5-1 plan | Aug 30, 2024 | 10-Q Oct 30, 2024 |
| Daniel Swisher Director |
Adopted 10b5-1 plan | Aug 1, 2024 | 10-Q Oct 30, 2024 |
| William Guyer Chief Development Officer |
Adopted 10b5-1 plan | Sep 14, 2023 | 10-Q Nov 1, 2023 |
| Sean Maduck President, Corcept Endocrinology |
Adopted 10b5-1 plan | Jun 20, 2023 | 10-Q Aug 2, 2023 |
| Dan Swisher Board of Director |
Adopted 10b5-1 plan | May 8, 2023 | 10-Q Aug 2, 2023 |
| J.D. Lyon Chief Accounting Officer |
Adopted 10b5-1 plan | May 8, 2023 | 10-Q Aug 2, 2023 |
Show the other 10 plans
From the XBRL of the company's 10-Qs and 10-Ks (Regulation S-K Item 408, reported since 2023): 15 filings checked since May 3, 2023.
Notices of planned sales
Form 144 · Form 144 XML, SEC
What the sellers expected to sell on the Form 144 notices filed each month (the value on the notice).
| Filed | Seller | Shares | Value |
|---|---|---|---|
| Nov 10, 2026 | DANIEL SWISHER JR. Director |
1,500 | $113K |
| Oct 1, 2026 | Lyon Joseph Douglas Officer |
10,000 | $1.2M |
| Sep 15, 2026 | WILSON JAMES N Director |
30,000 | $3.3M |
| Sep 14, 2026 | Lyon Joseph Douglas Officer |
10,000 | $1.1M |
| Sep 2, 2026 | Vieira Roberto Wandenkolk Officer |
75,295 | $8.3M |
| Aug 26, 2026 | KIMBERLY PARK Director |
26,685 | $3.3M |
| Aug 25, 2026 | Maduck Sean Officer |
175,000 | $22.0M |
| Aug 18, 2026 | MAHONEY DAVID L Director |
103,606 | $12.2M |
| Aug 17, 2026 | Robb Gary Charles Officer |
10,000 | $1.2M |
| Aug 4, 2026 | Guyer William Officer |
20,000 | $2.3M |
| Aug 3, 2026 | Lyon Joseph Douglas Officer |
1,540 | $176K |
| Jul 30, 2026 | Mokari Atabak Officer |
40,000 | $4.6M |
| Jul 7, 2026 | Guyer William Officer |
20,000 | $1.9M |
| Jun 16, 2026 | MAHONEY DAVID L Director |
20,000 | $1.7M |
| Jun 16, 2026 | WILSON JAMES N Director |
30,000 | $2.5M |
| Jun 2, 2026 | Guyer William Officer |
20,000 | $1.4M |
| Jun 1, 2026 | BELANOFF JOSEPH K Officer |
12,837 | $892K |
| Jun 1, 2026 | Mokari Atabak Officer |
160,000 | $11.2M |
| May 27, 2026 | Maduck Sean Officer |
150,000 | $9.8M |
| May 20, 2026 | Lyon Joseph Douglas Officer |
5,000 | $291K |
| May 5, 2026 | Guyer William Officer |
20,000 | $1.0M |
| May 1, 2026 | BELANOFF JOSEPH K Officer |
40,000 | $1.9M |
| Apr 7, 2026 | Guyer William Officer |
20,000 | $817K |
| Mar 25, 2026 | BELANOFF JOSEPH K Officer |
40,000 | $1.4M |
| Mar 4, 2026 | Guyer William Officer |
20,000 | $706K |
| Feb 3, 2026 | Guyer William Officer |
20,000 | $814K |
| Jan 6, 2026 | Guyer William Officer |
20,000 | $699K |
| Dec 2, 2025 | Guyer William Officer |
20,000 | $1.6M |
| Dec 1, 2025 | BELANOFF JOSEPH K Officer |
40,000 | $3.2M |
| Dec 1, 2025 | Maduck Sean Officer |
20,000 | $1.6M |
| Dec 1, 2025 | Lyon Joseph Douglas Officer |
5,000 | $397K |
| Nov 25, 2025 | Guyer William Officer |
4,500 | $364K |
Show the other 24 notices
From the Form 144 XML filed with the SEC, since Nov 25, 2025. The value is the seller's estimate on the notice. "Form 4 sales after" matches the seller's Form 4 sales in the 30 days after the notice, by name; Form 4s go back 180 days.
Sources
Regulation S-K Item 408 in the XBRL of each 10-Q and 10-K (since 2023); the Form 144 XML at the SEC.
Also
Insider trades: the Form 4s for the sales these plans led to.
Work with it
Excel workbook · CSV. Google Sheet that stays up to date: paste =IMPORTDATA("https://tickdelta.com/company/CORT/export.csv") into a cell.